Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Zopf, Dieter, Fichtner, Iduna, Bhargava, Ajay, Steinke, Wolfram, Thierauch, Karl‐Heinz, Diefenbach, Konstanze, Wilhelm, Scott, Hafner, Frank‐Thorsten, Gerisch, Michael
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Cancer Biology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5119973/
https://ncbi.nlm.nih.gov/pubmed/27734608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.883
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi